No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
AKRO Akero Therapeutics
- 19.740
- +0.810+4.28%
Close Apr 26 16:00 ET
- 19.420
- -0.320-1.62%
Post 19:13 ET
1.37BMarket Cap-6830P/E (TTM)
19.970High18.950Low753.13KVolume19.180Open18.930Pre Close14.76MTurnover1.33%Turnover RatioLossP/E (Static)69.15MShares58.38052wk High2.55P/B1.12BFloat Cap11.25052wk Low--Dividend TTM56.59MShs Float58.380Historical High--Div YieldTTM5.39%Amplitude7.520Historical Low19.592Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | B of A Securities Reinstates Neutral on Akero Therapeutics, Announces $30 Price Target
Akero Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/22/2024 44.51% B of A Securities → $30 Reinstates → Neutral 03/05/2024 102.31% UBS $39 → $42 Maintains
Hepion Ends Phase 2 Study for NASH Drug Due to Cash Restraints
Madrigal Announces US Launch of NASH/MASH Drug Rezdiffra
Akero Therapeutics(AKRO.US) Officer Sells US$121.91K in Common Stock
$Akero Therapeutics(AKRO.US)$ Officer Young Jonathan sold 5,000 shares of Common Stock on Apr 1, 2024 at an average price of $24.3826 for a total value of $121.91K.Source: Announcement What is stateme
Ademi LLP Investigates Claims of Securities Fraud Against Akero Therapeutics, Inc.
MILWAUKEE, April 2, 2024 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against Akero (Nasdaq: AKRO). The investigation results from inaccurate statements Akero may have
Comments
$Akero Therapeutics(AKRO.US$ Im done with medical stocks not a single one of these companies can make good decisions
For those that may be affected
$Akero Therapeutics(AKRO.US$ MILWAUKEE, April 2, 2024 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against Akero (Nasdaq: AKRO). The investigation results from inaccurate statements Akero may have made regarding its business operations and prospects.
Click here to learn more about the investigation: or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.
The investigation focuses on Akero's representations...
Click here to learn more about the investigation: or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.
The investigation focuses on Akero's representations...
$Akero Therapeutics(AKRO.US$ this been falling everday smh
According to Vantage market estimates for NASH could cross 100 Billion by 2030
NASH Basket- $Madrigal Pharmaceuticals(MDGL.US$$Viking Therapeutics(VKTX.US$$Akero Therapeutics(AKRO.US$$89bio(ETNB.US$
Than we already know how big Obesity market is going to be over next decade with global 1.5 Billion obese pts
Obesity Basket $Viking Therapeutics(VKTX.US$$Eli Lilly and Co(LLY.US$$Novo-Nordisk A/S(NVO.US$
NASH Basket- $Madrigal Pharmaceuticals(MDGL.US$$Viking Therapeutics(VKTX.US$$Akero Therapeutics(AKRO.US$$89bio(ETNB.US$
Than we already know how big Obesity market is going to be over next decade with global 1.5 Billion obese pts
Obesity Basket $Viking Therapeutics(VKTX.US$$Eli Lilly and Co(LLY.US$$Novo-Nordisk A/S(NVO.US$
6
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg